Until that time, healthcare providers are advised to consider the risks and benefits of cefepime therapy as described in the safety labeling and the meta-analysis.

• 到那时候，FDA将通知医疗供应商考虑安全标签和荟萃分析中描述的头孢吡肟疗法的风险获益。